The FDA has accepted Roche's New Drug Application for giredestrant, an investigational oral treatment for early-stage ER-positive, HER2-negative breast cancer. This acceptance is under Priority Review, indicating a potentially faster evaluation process. The decision is based on Phase III lidERA Breast Cancer study results. These results showed giredestrant reduced the risk of invasive disease recurrence or death by 30% compared to standard endocrine therapy. This represents a significant advance in adjuvant endocrine therapy in over two decades. Giredestrant has the potential to become a new standard of care, especially since most ER-positive breast cancers are diagnosed early. The FDA's decision is expected by November 30, 2026. Giredestrant works by degrading the estrogen receptor, thereby blocking cancer cell growth. The drug was also well-tolerated, with a lower discontinuation rate than standard treatment. Roche is committed to developing giredestrant for various breast cancer settings to improve patient outcomes.